Á¦³×¸¯ ÀǾàǰ
Generic Drugs
»óǰÄÚµå : 1648873
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 711 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå, 2030³â±îÁö 6,715¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 4,604¾ï ´Þ·¯·Î ÃßÁ¤µÈ ¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 6.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 6,715¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÀúºÐÀÚ Á¦³×¸¯ ÀǾàǰÀº CAGR 4.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5,388¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 16.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1,387¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀº 2024³â¿¡ 1,387¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1,268¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.7%¿Í 5.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¦³×¸¯ ÀǾàǰÀº ºê·£µå ÀǾàǰÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ÇコÄÉ¾î »ê¾÷¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀº ¿À¸®Áö³Î ÀǾàǰ°ú À¯È¿ ¼ººÐ, Á¦Çü, ¿ë·®, Åõ¿© °æ·Î, Ä¡·á È¿°ú°¡ µ¿ÀÏÇϹǷΠµ¿µîÇÑ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÕ´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀÇ Á¦Á¶´Â ¿À¸®Áö³Î ÀǾàǰÀÇ Æ¯Çã º¸È£°¡ ¸¸·áµÈ ÈÄ °¡´ÉÇØÁö±â ¶§¹®¿¡ ´Ù¸¥ Á¦Á¶¾÷ü°¡ µ¿ÀÏÇÑ ÀǾàǰÀ» ´õ Àú·ÅÇÑ °¡°ÝÀ¸·Î Á¦Á¶ ¹× ÆÇ¸ÅÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú °°Àº ±ÔÁ¦±â°üÀÌ °¨µ¶ÇÏ´Â Á¦³×¸¯ ÀǾàǰÀÇ ¾ö°ÝÇÑ ½ÂÀÎ ÀýÂ÷´Â Á¦³×¸¯ ÀǾàǰÀÌ Ç°Áú, ¼º´É ¹× ¶óº§¸µ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±âÁØÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇÕ´Ï´Ù.

Á¦³×¸¯ ÀǾàǰÀÇ º¸±ÞÀº ÀÇ·á ½Ã½ºÅÛ°ú ȯÀÚ ¸ðµÎ¿¡°Ô Áß¿äÇÑ Àǹ̸¦ °®½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀº º¸´Ù Àú·ÅÇÑ °¡°ÝÀÇ ¼±ÅñÇÀ» Á¦°øÇÔÀ¸·Î½á Àüü ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ°í ´õ ¸¹Àº »ç¶÷µéÀÌ ÀǾàǰÀ» ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ Àú·ÅÇÑ °¡°ÝÀº ȯÀÚ°¡ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ¾àÀ» º¹¿ëÇÏÁö ¾Ê°Å³ª Ä¡·á¸¦ Áß´ÜÇÒ °¡´É¼ºÀ» ³·Ãç Ä¡·á ¿ä¹ý ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦³×¸¯ ÀǾàǰÀÇ Á¢±Ù¼ºÀÌ ³ô¾ÆÁö¸é ÀǾàǰ ½ÃÀå¿¡¼­ÀÇ °æÀïÀÌ ÃËÁøµÇ¾î °¡°ÝÀÌ ´õ ³·¾ÆÁú ¼ö ÀÖ½À´Ï´Ù. º´¿ø, º¸Çè»ç ¹× Á¤ºÎ ÀÇ·á ÇÁ·Î±×·¥Àº ¿¹»êÀ» °ü¸®Çϰí ȯÀÚ¿¡°Ô Á¾ÇÕÀûÀÎ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ Á¦³×¸¯ ÀǾàǰ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ù°, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡¿Í °í·ÉÈ­·Î ÀÎÇØ ´Ù¾çÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× Áß »ó´ç¼ö°¡ Á¦³×¸¯À¸·Î Ãâ½ÃµÇ°í ÀÖ½À´Ï´Ù. ÀϺΠ°í¸ÅÃâ ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÊ¿¡ µû¶ó Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü°¡ ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» µµÀÔÇÒ ¼ö ÀÖ´Â ±æÀÌ ¿­·È½À´Ï´Ù. ¶ÇÇÑ ÀǾàǰ Á¦Á¶ ±â¼úÀÇ ¹ßÀüÀº Á¦³×¸¯ ÀǾàǰÀÇ »ý»ê È¿À²¼º°ú ºñ¿ë È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. Á¦³×¸¯ ÀǾàǰ°ú ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ½ÂÀÎ ÀýÂ÷¸¦ ½Å¼ÓÈ÷ ó¸®ÇÏ·Á´Â ±ÔÁ¦ ´ç±¹ÀÇ ³ë·Âµµ ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁö°í ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â µî ¼ÒºñÀÚ ÇൿÀÇ º¯È­µµ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ÀÇ·á ¼ö¿ä°¡ Áõ°¡Çϰí ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÖ´Â ½ÅÈï ½ÃÀåÀº Á¦³×¸¯ Á¦¾à»çµé¿¡°Ô »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¾ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼¼°è Á¦³×¸¯ ÀǾàǰÀÇ °ß°íÇÑ ¼ºÀå°ú º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(ÀúºÐÀÚ Á¦³×¸¯ ÀǾàǰ, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ); & Ä¡·á ¿ëµµ(¼øÈ¯±â, ÁßÃ߽Űæ°è(CNS), ÇǺΰú, Á¾¾ç, È£Èí±â, ±âŸ Ä¡·á ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 255»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Generic Drugs Market to Reach US$671.5 Billion by 2030

The global market for Generic Drugs estimated at US$460.4 Billion in the year 2024, is expected to reach US$671.5 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Small-Molecule Generics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Growth in the Biosimilars segment is estimated at 16.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$138.7 Billion While China is Forecast to Grow at 8.1% CAGR

The Generic Drugs market in the U.S. is estimated at US$138.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Generic Drugs Market - Key Trends & Drivers Summarized

Generic drugs play a pivotal role in the healthcare industry by providing cost-effective alternatives to brand-name medications. These drugs contain the same active ingredients, dosage form, strength, route of administration, and therapeutic effects as their branded counterparts, ensuring they are equally safe and effective. The production of generic drugs becomes possible after the patent protections on brand-name drugs expire, allowing other manufacturers to create and market the same medication at a lower price. The rigorous approval process for generics, overseen by regulatory bodies such as the U.S. Food and Drug Administration (FDA), ensures that these drugs meet stringent standards for quality, performance, and labeling.

The widespread use of generic drugs has significant implications for both healthcare systems and patients. By offering more affordable options, generics help to reduce the overall cost of healthcare, making medications more accessible to a larger portion of the population. This affordability can lead to improved adherence to treatment regimens, as patients are less likely to skip doses or abandon treatment due to high costs. Moreover, the increased availability of generic drugs fosters competition in the pharmaceutical market, which can drive down prices even further. Hospitals, insurance companies, and government healthcare programs heavily rely on generic drugs to manage budgets and provide comprehensive care to patients.

The growth in the generic drugs market is driven by several factors. Firstly, the rising incidence of chronic diseases and an aging population increase the demand for various medications, many of which are available as generics. The expiration of patents on several high-revenue drugs opens the door for generic manufacturers to introduce cost-effective alternatives. Additionally, technological advancements in pharmaceutical manufacturing enhance the efficiency and cost-effectiveness of producing generic drugs. Regulatory initiatives aimed at speeding up the approval process for generics and biosimilars also play a crucial role in market expansion. Consumer behavior trends, such as increased trust in generic medications and a greater focus on reducing healthcare expenditures, further propel market growth. Lastly, emerging markets with growing healthcare needs and improving healthcare infrastructure present new opportunities for generic drug manufacturers. These factors collectively drive the robust growth and adoption of generic drugs globally.

SCOPE OF STUDY:

The report analyzes the Generic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Small-Molecule Generics, Biosimilars); Therapeutic Application (Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory, Other Therapeutic Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 255 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â